Pharma BD Deal Intelligence

Celgene Corporation / OncoMed Pharmaceuticals Inc.

2013 · Co-Development · $3.3B · Complete

Announcement Sentiment

Strongly positive

Celgene/OncoMed global co-dev/co-commercialization for demcizumab plus 5 cancer stem cell biologics; ~$155M upfront + $22.25M equity + ~$3B in potential milestones plus royalties.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Dec 02, 2013
Closed Dec 02, 2013
Deal value $3.3B
Deal type Co-Development
Therapeutic area Solid tumors (oncology)
Indications Solid tumors (oncology)
Key assets Demcizumab (anti-DLL4) plus 5 additional biologics targeting cancer stem cell pathways
Mechanism Anti-DLL4 mAb and other cancer stem-cell pathway biologics

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals